{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:14:52Z","timestamp":1793672092194,"version":"4.5.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["22HA1004"],"award-info":[{"award-number":["22HA1004"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","jiac-j.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jiac.2024.03.010","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T17:35:30Z","timestamp":1710351330000},"page":"989-994","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Potential risk factors for early acute kidney injury in patients treated with vancomycin"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4534-8433","authenticated-orcid":false,"given":"Aiju","family":"Endo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumi","family":"Hanawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Asakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7636-9334","authenticated-orcid":false,"given":"Taiki","family":"Ishibe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Nakane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2024.03.010_bib1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3390\/pharmaceutics14030489","article-title":"Clinical practice guidelines for therapeutic drug monitoring of vancomycin in the framework of model\u2013informed precision dosing: a consensus review by the Japanese society of chemotherapy and the Japanese society of therapeutic drug monitoring","volume":"14","author":"Matsumoto","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jiac.2024.03.010_bib2","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jiac.2024.03.010_bib3","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/cid\/ciaa1744","article-title":"Vancomycin area under the curve\u2013guided dosing and monitoring for adult and pediatric patients with suspected or documented serious methicillin\u2013resistant Staphylococcus aureus infections: putting the safety of our patients first","volume":"72","author":"Lodise","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2024.03.010_bib4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12879-021-05858-6","article-title":"The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration\u2013time curve\u2013guided dosing and trough\u2013guided dosing","volume":"21","author":"Tsutsuura","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jiac.2024.03.010_bib5","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/cid\/ciu398","article-title":"Vancomycin exposure in patients with methicillin\u2013resistant Staphylococcus aureus bloodstream infections: how much is enough?","volume":"59","author":"Lodise","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2024.03.010_bib6","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1128\/AAC.03970-14","article-title":"Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin\u2013resistant Staphylococcus aureus infective endocarditis","volume":"59","author":"Casapao","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.03.010_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146224","article-title":"Association between the AUC0\u221224\/MIC ratio of vancomycin and its clinical effectiveness: a systematic review and meta\u2013analysis","volume":"11","author":"Men","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jiac.2024.03.010_bib8","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/phar.1638","article-title":"Vancomycin trough concentration as a predictor of clinical outcomes in patients with Staphylococcus aureus bacteremia: a meta\u2013analysis of observational studies","volume":"35","author":"Prybylski","year":"2015","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jiac.2024.03.010_bib9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ijantimicag.2012.10.015","article-title":"Vancomycin pharmacodynamics and survival in patients with methicillin\u2013resistant Staphylococcus aureus\u2013associated septic shock","volume":"41","author":"Zelenitsky","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2024.03.010_bib10","doi-asserted-by":"crossref","DOI":"10.1111\/1469-0691.12695","article-title":"Impact of source of infection and vancomycin AUC0\u221224\/MICBMD targets on treatment failure in patients with methicillin\u2013resistant Staphylococcus aureus bacteraemia","volume":"20","author":"Ghosh","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jiac.2024.03.010_bib11","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijantimicag.2013.10.017","article-title":"Area under the concentration\u2013time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin\u2013resistant Staphylococcus aureus bacteraemia","volume":"43","author":"Jung","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2024.03.010_bib12","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.ijantimicag.2015.09.010","article-title":"Impact of area under the concentration\u2013time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin\u2013resistant Staphylococcus aureus bacteraemia","volume":"46","author":"Song","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2024.03.010_bib13","doi-asserted-by":"crossref","first-page":"218","DOI":"10.5114\/ait.2019.87362","article-title":"Association between single trough\u2013based area under the curve estimation of vancomycin and treatment outcome among methicillin\u2013resistant Staphylococcus aureus bacteremia patients","volume":"51","author":"Makmor-Bakry","year":"2019","journal-title":"Anaesthesiol Intensive Ther"},{"key":"10.1016\/j.jiac.2024.03.010_bib14","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01684-17","article-title":"Identification of vancomycin exposure\u2013toxicity thresholds in hospitalized patients receiving intravenous vancomycin","volume":"62","author":"Zasowski","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.03.010_bib15","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01293-17","article-title":"A quasi\u2013experiment to study the impact of vancomycin area under the concentration\u2013time curve\u2013guided dosing on vancomycin\u2013associated nephrotoxicity","volume":"61","author":"Finch","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.03.010_bib16","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/cid\/ciz460","article-title":"The emperor's new clothes: prospective observational evaluation of the association between initial vancomycin exposure and failure rates among adult hospitalized patients with methicillin\u2013resistant Staphylococcus aureus bloodstream infections (PROVIDE)","volume":"70","author":"Lodise","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2024.03.010_bib17","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1093\/cid\/ciz051","article-title":"Vancomycin area under the curve and acute kidney injury: a meta\u2013analysis","volume":"69","author":"Aljefri","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2024.03.010_bib18","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02535-16","article-title":"Establishment of an AUC0\u201324 threshold for nephrotoxicity is a step towards individualized vancomycin dosing for methicillin\u2013resistant Staphylococcus aureus bacteremia","volume":"61","author":"Chavada","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.03.010_bib19","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/phar.2234","article-title":"Conversion from vancomycin trough concentration-guided dosing to area under the curve\u2013guided dosing using two sample measurements in adults: implementation at an Academic Medical Center","volume":"39","author":"Meng","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jiac.2024.03.010_bib20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12941-020-00354-2","article-title":"The risk of vancomycin toxicity in patients with liver impairment","volume":"19","author":"Brunetti","year":"2020","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.jiac.2024.03.010_bib21","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000343162","article-title":"Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic\u2013pharmacodynamic analysis in patients with methicillin\u2013resistant Staphylococcus aureus pneumonia","volume":"58","author":"Suzuki","year":"2012","journal-title":"Chemotherapy"},{"key":"10.1016\/j.jiac.2024.03.010_bib22","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jiac.2020.10.014","article-title":"Comparison of trough concentration and area under the curve of vancomycin associated with the incidence of nephrotoxicity and predictors of a high trough level","volume":"27","author":"Suzuki","year":"2021","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2024.03.010_bib23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jgar.2021.07.018","article-title":"Candidates for area under the concentration\u2013time curve (AUC)\u2013guided dosing and risk reduction based on analyses of risk factors associated with nephrotoxicity in vancomycin\u2013treated patients","volume":"27","author":"Hashimoto","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jiac.2024.03.010_bib24","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3390\/antibiotics11010096","article-title":"Validation of vancomycin area under the concentration-time curve estimation by the Bayesian approach using one\u2013point sample for predicting nephrotoxicity and clinical outcomes in patients with methicillin-resistant Staphylococcus aureus infections","volume":"11","author":"Ueda","year":"2022","journal-title":"Antibiotics"},{"key":"10.1016\/j.jiac.2024.03.010_bib25","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1053\/j.ajkd.2013.02.350","article-title":"Canadian Society of Nephrology commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury","volume":"61","author":"James","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jiac.2024.03.010_bib26","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s10157-018-1600-4","article-title":"The Japanese clinical practice guideline for acute kidney injury 2016","volume":"22","author":"Doi","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.jiac.2024.03.010_bib27","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.jiac.2024.03.010_bib28","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s13340-020-00439-5","article-title":"Japanese clinical practice guideline for diabetes 2019","volume":"11","author":"Araki","year":"2020","journal-title":"Diabetol Int"},{"key":"10.1016\/j.jiac.2024.03.010_bib29","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1159\/000531511","article-title":"Vancomycin hydrochloride as a risk factor for acute kidney injury: a retrospective study","volume":"108","author":"Uekusa","year":"2023","journal-title":"Pharmacology"},{"key":"10.1016\/j.jiac.2024.03.010_bib30","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s11095-021-03030-y","article-title":"Performance of area under the concentration\u2013time curve estimations of vancomycin with limited sampling by a newly developed web application","volume":"38","author":"Oda","year":"2021","journal-title":"Pharm Res (N Y)"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X24000850?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X24000850?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:31:37Z","timestamp":1724373097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X24000850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1341321X24000850"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2024.03.010","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential risk factors for early acute kidney injury in patients treated with vancomycin","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2024.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}